An Oregon review panel established under the state’s voter-approved therapeutic psilocybin legalization initiative has released a report stating that the psychedelic holds significant medical value for a number of mental health conditions.
After reviewing about 600 studies that looked into psilocybin, a subcommittee of the Oregon Psilocybin Advisory Board determined that the substance is shown to be “efficacious in reducing depression and anxiety, including in life-threatening conditions.”
It noted that the studies that were under review all involved administration in a clinically supervised setting, which is also required under Oregon’s psilocybin program.
“Across studies, psilocybin increases spiritual well-being which may mediate other observed benefits,” the report, which is the product of eight weeks of review, states. “Study participants also commonly rate their psilocybin experiences as highly meaningful.”
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers